Search Results - "Pinter T"

Pharmaceutical company payments to Japanese breast cancer practice guideline authors.

Authors: Murayama, Anju Higuchi, Kenichi Byreddy, Keerthana R. et al.

Source: Clinical & Translational Discovery. Jun2024, Vol. 4 Issue 3, p1-14. 14p.

A cell-nonautonomous heme acquisition pathway enables erythroid hemoglobinization under stress.

Authors: Belot, Audrey Rock, Andrew Dutt, Sohini et al.

Source: Science. 4/23/2026, Vol. 392 Issue 6796, p388-394. 7p.

Influence of Process Parameters on the Forming Quality and Metal Flow Characteristics of the Billet During Hot Extrusion of an Automotive Luggage Rack.

Authors: Cheng, Anna Shu, Xuedao Zhang, Dewei et al.

Source: Metals (2075-4701); Jun2026, Vol. 16 Issue 6, p637, 22p

Notes on Contributors.

Source: Irish University Review; Nov2022, Vol. 52 Issue 2, pxi-xv, 5p

Experimental and Numerical Investigation of Liquid Nitrogen Die Cooling for Increased Efficiency in Porthole Aluminum Extrusion Dies.

Authors: Giarmas, Evangelos Theodoridis, Ioannis Tounis, Panagiotis et al.

Source: Applied Sciences (2076-3417); Mar2026, Vol. 16 Issue 5, p2385, 35p

New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study.

Authors: Karpinski MJ Civan C Rauscher I et al.

Corporate Authors: Karpinski MJ Civan C Rauscher I et al.

Source: The Lancet. Oncology [Lancet Oncol] 2026 Apr; Vol. 27 (4), pp. 480-490. Date of Electronic Publication: 2026 Mar 09.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

Geriatric Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024.

Authors: Wolf, Clemens Wedding, Ulrich

Source: Oncology Research & Treatment. 2025, Vol. 48 Issue 9, p558-562. 4p.

Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status.

Authors: Bittner, Madison Llaurado Fernandez, Marta Hoenisch, Joshua et al.

Source: International Journal of Molecular Sciences. Feb2026, Vol. 27 Issue 4, p1774. 24p.

The Prognostic and Predictive Value of Body Mass Index in Patients with HR+/HER2− Breast Cancer Treated with CDK4/6 Inhibitors: A Systematic Literature Review.

Authors: Badau, Larisa Maria Oprean, Cristina Marinela Ciocoiu, Andrei Dorin et al.

Source: Cancers. Jan2026, Vol. 18 Issue 1, p81. 14p.

Palbociclib in Combination with Endocrine Therapy in Patients with Metastatic Breast Cancer in a Real-World Population: Impact of Dose-Intensity, Dose Reductions and Cycle Delays on Efficacy.

Authors: Coussirou, Julie Grenier, Julien Mege, Alice et al.

Source: Current Oncology. Jan2026, Vol. 31 Issue 1, p51. 12p.

Survival Benefits of Palbociclib Plus Endocrine Therapy in HR+/HER2- Advanced Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Trials.

Authors: Mansouri, Nasrin Mirbahari, Seyed Ghasem Zandian, Roya et al.

Source: Journal of Reports in Pharmaceutical Sciences. Dec2025, Vol. 13 Issue 1, p1-8. 8p.

Microbiological profile and 30-day mortality outcomes in febrile neutropenia among solid malignancy patients: a multicentre retrospective study from resource-limited setting.

Authors: Dracham, Chinna Babu Bandanatham, Sweta Dumpala, Venkata Ravi Kiran et al.

Source: Scientific Reports. 11/5/2025, Vol. 15 Issue 1, p1-13. 13p.

CDK4/6 Inhibitors Suppress RB-Null Triple-Negative Breast Cancer by Inhibiting Mutant P53 Expression via RBM38 RNA-Binding Protein.

Authors: Zhang, Jin Wen, Kexin Nakajima, Ken-ichi et al.

Source: Cancers. Oct2025, Vol. 17 Issue 20, p3339. 15p.

Oncologic Outcomes and Safety of Neoadjuvant Treatment with Anthracyclines Versus Anthracycline-Free Regimens in HER2-Positive Early Breast Cancer in a Colombian Cancer Center: An Observational, Analytical, Retrospective Study.

Authors: Acevedo-Ramos, Alfredo Zuluaga-Liberato, Andrea Díaz-Casas, Sandra E.

Source: Cancers. Oct2025, Vol. 17 Issue 19, p3190. 13p.

A scintillator plus silicon photomultiplier heavy-ion detector array for g-factor measurements by the time-differential recoil-in-vacuum method.

Authors: Woodside, Jack Stuchbery, Andrew McCormick, Brendan et al.

Source: EPJ Web of Conferences. 5/13/2026, Vol. 367, p1-5. 5p.

Synthesis of Nitriles from Dinitrogen via N‐Atom Transfer on Rhenium Nitride Complex.

Authors: Shan, Chunxiao Wu, Yue Yin, Zhu‐Bao et al.

Source: Angewandte Chemie. 7/1/2025, Vol. 137 Issue 27, p1-7. 7p.

Molecular Profiling and Targeted Therapeutic Strategies in Breast Cancer: Clinical Integration of HER2, CDK4/6, and PI3K Inhibition with Trastuzumab, Abemaciclib and Alpelisib.

Authors: Kawczak, Piotr Bączek, Tomasz

Source: Journal of Clinical Medicine. May2026, Vol. 15 Issue 10, p3715. 40p.

Mechanism-Based Strategies for Prevention of Taxane-Induced Hair Follicle Damage in Cancer Chemotherapy.

Authors: Amaya, Celina Schlumbrecht, Matthew P. Wikramanayake, Tongyu C. et al.

Source: Cancers. May2026, Vol. 18 Issue 9, p1351. 13p.

CDK4/6 Inhibitors for Breast Cancer Therapy—A Review of Clinical Trials, Structural and Computational Approaches.

Authors: Avdičević, Adela Lešnik, Samo Bren, Urban et al.

Source: Pharmaceuticals (14248247). Apr2026, Vol. 19 Issue 4, p610. 47p.

The Xbp1-regulated transcription factor Mist1 restricts antibody secretion by restraining Blimp1 expression in plasma cells.

Authors: Wöhner M Pinter T Bönelt P et al.

Source: Frontiers in immunology [Front Immunol] 2022 Dec 21; Vol. 13, pp. 859598. Date of Electronic Publication: 2022 Dec 21 (Print Publication: 2022).

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE